Wonil Lee, M.D.
Specialist
12660 Riverside Dr, Suite 200
North Hollywood, CA 91607
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 34
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 757
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Specialist primary
CA license A54116
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Providence Saint Joseph Medical Ctr Burbank, CA
Medical groups
- Center for Rheumatology Medical Corporation (9 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 757
- Services billed
- 252,117
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 57,206 | 27 |
| Injection, romosozumab-aqqg, 1 mg | 40,110 | 36 |
| Injection, denosumab, 1 mg | 20,942 | 222 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 7,425 | 11 |
| Established patient office or other outpatient visit, 30-39 minutes | 2,061 | 667 |
| Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | 1,568 | 20 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 1,013 | 262 |
| Infusion, normal saline solution, 250 cc | 274 | 44 |
| Administration of chemotherapy into vein, 1 hour or less | 274 | 44 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 259 | 106 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Methotrexate (methotrexate sodium) Other prescribers in North Hollywood, CA | 337 |
| Prednisone Other prescribers in North Hollywood, CA | 311 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in North Hollywood, CA | 300 |
| Hydroxychloroquine Sulfate Other prescribers in North Hollywood, CA | 230 |
| Gabapentin Other prescribers in North Hollywood, CA | 141 |
| Meloxicam Other prescribers in North Hollywood, CA | 110 |
| Zolpidem Tartrate Other prescribers in North Hollywood, CA | 105 |
| Celecoxib Other prescribers in North Hollywood, CA | 98 |
| Tramadol Hcl Other prescribers in North Hollywood, CA | 90 |
| Colchicine Other prescribers in North Hollywood, CA | 85 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 132 payments worth $3,621 in total to this clinician.
| Amgen Inc. | $721 |
|---|---|
| Novartis Pharmaceuticals Corporation | $585 |
| AbbVie Inc. | $538 |
| Pfizer Inc. | $279 |
| Janssen Biotech, Inc. | $215 |
| Tersera Therapeutics LLC | $183 |
| UCB, Inc. | $164 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $158 |
| Food and Beverage | $3,621 |
|---|---|
| Education | $0.80 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Amgen Inc. Jul 25, 2025 | Education KRYSTEXXA · Inflammation/Rare Disease · in-kind | $0.80 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $24,174 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis
Sanofi US Services Inc. · Completed · NCT06073093 - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgrens Syndrome With Moderate-to-Severe Systemic Disease Activity
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.